Cannabinor

Cannabinor, also designated PRS-211375, is a synthetic agonist selective for the cannabinoid CB2 receptor, present notably in the urothelium and sensory nerves of the bladder according to the 2010 study. The inhibition constants recorded are 9.0 nM at CB2 and 334 nM at CB1 (Han et al., 2013). A functional selectivity of 321-fold in favour of CB2 is reported (Gratzke et al., 2010). In rat bladder models, a daily dose of 3 mg/kg for 14 days reduced bladder weight and preserved its emptying capacity during partial urethral obstruction (Gratzke et al., 2011). ChEMBL classes the molecule at phase 2 of clinical trials, but no published human data was found in the sources consulted.

Source

Fully synthetic molecule, not recorded in hemp according to the reference data consulted. It combines a resorcinol nucleus bearing a 1,1-dimethylheptyl chain, a pinane-type bicyclic fragment carrying a ketone, and a fumaric acid half-ester. The 2011 urology study associates the molecule with Procter & Gamble Pharmaceuticals (Cincinnati).

No known biosynthetic pathway: it is a chemically synthesised compound, with no known plant or animal origin.

European Union

No harmonised control measure at European Union level was found in the sources consulted: where control exists, it falls under national regimes.

France

Cannabinor is not named in any annex of the ANSM consolidated list of narcotics (updated 16 February 2026). The closest generic clause is the cyclohexylphenol clause, which covers cyclohexylphenols or derivatives of 2-(3-hydroxycyclohexyl)phenol, with a substituent at position 5 of the phenol ring. The 1,1-dimethylheptyl chain does occupy position 5, but the terpenic ring, which carries a carbon bridge, bears a ketone rather than a hydroxyl: on the wording of the clause, it therefore does not cover this structure, and no source consulted settles how the clause should be read. The other generic clauses examined (tetrahydrocannabinols, benzo[c]chromenes, indoles and indazoles) do not match its structure. The molecule is therefore unscheduled in France, which does not amount to an authorisation: its use falls within research.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

1. 1Gratzke et coll., effets du cannabinor sur la fonction vésicale du rat sain, Eur Urol 2010 (new tab)PMID 20207474
2. 2Gratzke et coll., cannabinor et vidange vésicale en obstruction urétrale partielle, J Urol 2011 (new tab)PMID 21168864
3. 3Bouma et coll., test cinétique multiplexe des agonistes cliniques du CB2, Pharmacol Res 2025 (new tab)PMID 41205725
4. 4Han et coll., utilité thérapeutique des agonistes sélectifs du CB2, J Med Chem 2013 (new tab)PMID 23865723
5. 5PubChem, fiche du composé CID 10174045 (new tab)
6. 6ChEMBL, fiche du composé CHEMBL3234035 (PRS-211375) (new tab)
7. 7ANSM, liste consolidée des stupéfiants, mise à jour du 16 février 2026 (new tab)
8. 8INCB, Liste verte 2026 (tableaux de la Convention de 1971) (new tab)

SMILES

CCCCCCC(C)(C)C1=CC(=C(C(=C1)OC(=O)/C=C/C(=O)O)[C@H]2CC(=O)[C@H]3C[C@@H]2C3(C)C)O

InChIKey

GSTZHANFXAKPSE-MXTREEOPSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.